Short answer
Rezolute, Inc. (RZLT) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Investor Presentation released October 29, 2026, signaling management’s current messaging for investors and business stakeholders.
Rezolute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor Presentation released October 29, 2026, signaling management’s current messaging for investors and business stakeholders
- Exhibit 99.1 contains the substantive company outlook and strategy details requiring investor review
- Presentation includes forward-looking statements, making execution and forecast risk key considerations
- Disclosure furnished under Regulation FD, generally not filed under Exchange Act Section 18 liability standards
Item EX-99.1 · Exhibit EX-99.1
- Cash $108M, runway through Q1 2028, supporting execution without near-term financing pressure
- Congenital HI Phase 3 completed, with FDA encouraging a Type B pre-BLA meeting before potential 2027 BLA filing
- Primary sunRIZE SMBG endpoint missed, while CGM showed reductions exceeding 50% versus placebo at select timepoints
- Tumor HI upLIFT interim data: 7 of 8 participants met the primary endpoint and discontinued intravenous glucose
- Combined addressable opportunity exceeds $5B, including approximately 6,000 U.S. patients across congenital and tumor HI
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rezolute, Inc. 8-K filings
Get the next RZLT 8-K as it lands
Follow RZLT for push alerts, or ask the research agent what this filing means.